Savvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over the last 14 days and assigns a value from 0 to 100.

Bristol Myers and Pfizer have experienced declining sales lately. However, both companies are rejuvenating their lineups.

Bristol Myers stock is trading at multi-year lows and offers a sizable dividend yield. The drugmaker's scary-looking net loss is largely attributable to one-time outlays.

Bristol-Myers Squibb's share price reached new all-time highs in 2022, driven by a strong pipeline and new approvals. However, doubts arose about the company's ability to close the patent gap and a...

The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.

A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U...

AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol-Myers Squibb has a strong pipeline...

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics c...

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance.

Bristol Myers Squibb beat Wall Street estimates in the first quarter. However, the company slashed its full-year earnings outlook because of recent acquisitions and collaborations.

Bristol-Myers Squibb (NYSE: BMY ) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce. Bristol-Myers Squibb has revealed that it...

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics c...

The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.

Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.9...